New patent for Alkermes Inc drug LYBALVI

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

Annual Drug Patent Expirations for LYBALVI
Annual Drug Patent Expirations for LYBALVI

Lybalvi is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug.

This drug has fifty-eight patent family members in twenty-six countries.

The generic ingredient in LYBALVI is olanzapine; samidorphan l-malate. One supplier is listed for this compound. Additional details are available on the olanzapine; samidorphan l-malate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Make Better Decisions
Scroll to Top